Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Silence Therapeutics Makes Non-Exec Changes

This article was originally published in Scrip

Executive Summary

Silence Therapeutics Plc. has appointed Stuart Collinson non-executive director of the company and Simon Sturge, current non-executive director, has resigned because of other business commitments – effective immediately. Sturge has also resigned from the company's board and Collinson will chair the remuneration committee. Collinson is a partner of Forward Ventures, a biopharmaceutical venture capital fund, chair and CEO of Tioga Pharmaceuticals, Inc., director of Arcturus Therapeutics, Inc., and Essentialis. Previously, Collinson was chair, CEO and president of Aurora Bioscience Corp., which was acquired by Vertex Pharmaceuticals. Inc., after which he became director of the company. He has also held senior management positions at GlaxoWellcome Plc. (now GlaxoSmithKline Plc.) and Baxter International.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel